Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
9/1/2010 8:42:05 AM
More...
|
Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
8/25/2010 10:12:23 AM
More...
|
Roche (RHHBY) (JOBS) Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
12/16/2009 6:31:41 AM
More...
|